More on VTGN
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.28 |
|
|||
| Open | $0.29 | ||||
| 52 Wk High | $4.60 | ||||
| 52 Wk Low | $2.81 | ||||
| Day High | $0.31 | ||||
| Day Low | $0.28 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 2,555,764 | ||||
- Form 8-K Vistagen Therapeutics, For: Aug 06
- Vistagen reports Phase 2 repeat dose results for fasedienol in SAD
- Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
- Form 8-K Vistagen Therapeutics, For: Aug 04
- SRX Global acquires stake in Vistagen Therapeutics
- SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)
- Form DEFA14A Vistagen Therapeutics,
- Form DEF 14A Vistagen Therapeutics, For: Jul 31
- Form 4 Vistagen Therapeutics, For: Jul 29 Filed by: Williamson Douglas J
- Form 3 Vistagen Therapeutics, For: Jul 29 Filed by: Williamson Douglas J
Entities mentioned with VTGN
- FDA | View Related Stories »
- Twitter | View Related Stories »
- 13G | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- William Blair | View Related Stories »
- S3 | View Related Stories »
- Dividend | View Related Stories »
- Show More...
